Venture Partner
Hatteras Venture PartnersCheck size: Not publicly specified on the official site
At the firm level, Hatteras Venture Partners builds transformational healthcare companies across biotechnology, medical technology, and health technology with a patient-impact focus.
Hatteras Venture Partners's published criteria emphasize high-quality science and teams capable of producing breakthrough therapeutic, diagnostic, medical-device, or healthcare outcomes. This is firm-level context, not an unsupported personal attribution.
No person-specific exclusions were published. At the firm level, companies outside human health or without a credible path to patient impact and value-creating milestones are unlikely to fit.
Use Hatteras Venture Partners's official contact or application channel. Lead with fit to Early stage through value inflection and liquidity, explain why the company matches Biotechnology, medical technology, and health technology, and support claims with traction and a concise use-of-capital plan.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Myla Lai-Goldman is listed by Hatteras Venture Partners on its current official team roster as Venture Partner. No additional personal claims are made without an official source.